mogamulizumab


( Last Updated : October 14, 2021)
Generic Name:
mogamulizumab
Project Status:
Active
Therapeutic Area:
mycosis fungoides (MF), Sézary syndrome (SS)
Manufacturer:
Kyowa Kirin Canada
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
PC0244-000
Tumour Type:
Lymphoma
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
The treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy (per Product Monograph).
Submission Type:
Initial
Fee Schedule:
Schedule A
Tumour Type:
Lymphoma
Indications:
The treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open13-Aug-21
Call for patient/clinician input closed08-Oct-21
Clarification:

- Patient input submission received from Lymphoma Canada, Canadian Skin Patient Alliance and Cutaneous Lymphoma Foundation.

Submission received13-Sep-21
Submission accepted27-Sep-21
Review initiated28-Sep-21
Draft CADTH review report(s) provided to sponsor for comment10-Dec-21
Deadline for sponsors comments21-Dec-21
CADTH review report(s) and responses to comments provided to sponsor28-Jan-22
Expert committee meeting (initial)09-Feb-22
Draft recommendation issued to sponsorFebruary 22, 2022
To
February 24, 2022
Draft recommendation posted for stakeholder feedback
End of feedback period